[1]王任飞,谭建,张桂芝,等.131I治疗对Graves眼病转归的影响[J].国际放射医学核医学杂志,2011,35(4):223-227.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
　WANG Ren-fei,TAN Jian,ZHANG Gui-zhi,et al.Effect of 131I therapy on outcomes of Graves’ ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):223-227.[doi:10.3760/cma.j.issn.1673-4114.2011.04.007]
点击复制

131I治疗对Graves眼病转归的影响(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
35
期数:
2011年第4期
页码:
223-227
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Effect of 131I therapy on outcomes of Graves’ ophthalmopathy
作者:
王任飞;  谭建;  张桂芝;  尹亮
天津医科大学总医院核医学科, 天津 300052
Author(s):
WANG Ren-fei;  TAN Jian;  ZHANG Gui-zhi;  YIN Liang
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
Graves眼病; 碘放射性同位素; 药物疗法
Keywords:
Graves ophthalmopathy; Iodine radiosotopes; Drug therapy
DOI:
10.3760/cma.j.issn.1673-4114.2011.04.007
摘要:
目的 分析131I治疗后Graves甲状腺功能亢进症(甲亢)疗效与Graves眼病转归的相关关系,探讨131I治疗对Graves眼病转归的影响。方法 652例Graves甲亢合并Graves眼病的患者,均按照常规程序一次性给予治疗量的131I。服用131I前测量患者眼球突出度,并详细记录眼部症状和特征。治疗结束后定期随访,评价疗效。结果 患者服用131I后Graves甲亢治疗的总有效率约为94.3%,Graves眼病的总好转率约为73.3%,而Graves甲亢及Graves眼病治疗均有效者约占总病例数的71.2%。131I治疗后Graves眼病的转归与Graves甲亢是否得到有效缓解具有明显的相关性(r=0.302,P<0.05)。131I治疗后Graves甲亢治愈组与甲状腺功能减退症(甲减)组比较,Graves眼病的疗效差异无统计学意义(χ2=0.296,P>0.05)。结论 通过131I治疗来缓解Graves甲亢是控制Graves眼病的根本措施。患者服用131I后加强随访,及时发现和纠正甲减可有效避免Graves眼病的加重。
Abstract:
Objective To analyze the correlation between the therapeutic effect of Graves, hyperthyroidism and the outcomes of Graves’ ophthalmopathy after 131I therapy, and to explore the effect of 131I treatment on turnout of Graves’ ophthalmopathy. Methods Six hundreds and fifty-two patients of Graves’ disease accompanied with Graves’ ophthalmopathy, received one-time treatment according to routine procedure. We recorded exophthalmometer readings, the signs and symptoms of eyes before therapy. Regular follow-up and appraisal of curative effect were carried out. Results At least six months after 131I therapy, the effective rate of Graves’ hyperthyroidism and Graves’ ophthalmopathy were 94.3% and 73.3% respectively. The total effective rate of hyperthyroidism with ophthalmophy was 71.2%. There was a significant correlation between the prognosis of Graves’ ophthalmopathy and therapeutic efficacy of hyperthyroidism(r=0.302, P<0.05). The outcomes of Graves’ ophthalmopathy had no statistically differences between cured and hypothyroidism groups after 131I therapy(χ2=0.296, P>0.05). Conclusions The key to treat Graves’ ophthalmopathy is the cure of Graves’ hyperthyroidism through 131I therapy. The timely diagnosis and replacement treatment of hypothyroidism can effectively avoid the aggravation of Graves’ ophthalmopathy after 131I therapy.

参考文献/References:

[1] Bahn RS.Graves’ ophthalmopathy.New Engl J Med,2010,362(8):726-738.
[2] 中华医学会内分泌学分会《中国甲状腺疾病诊断指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症.中华内科杂志,2007,46(10):876-882.
[3] Bartalena L,Baldeschi L,Dickinson A,et al.Consensus statement of the European Group on Graves’ orbitopathy(EUGOGO) on management of GO.Eur J Endocrinol,2008,158(3):273-285.
[4] 谭建,张桂芝,周荫保.131I治疗甲亢剂量的实用计算方法及应用.中国地方病防治杂志,1995,10(增刊)21-22.
[5] Bartalena L,Tanda ML.Clinical practice of Graves’ ophthalmopathy.N Engl J Med,2009,360(10):994-1001.
[6] 蒋宁一,匡安仁,谭建,等.131I治疗Graves甲亢专家共识(2010年),中华核医学杂志,2010,30(5):346-351.
[7] 桑士标,李清茹,吴翼伟,等.云克治疗甲亢伴浸润性突眼的疗效分析.苏州大学学报(医学版),2005,25(6):1106-1107.
[8] 王新民,徐晨,李路.Graves病459例5年追踪研究.中国实用内科杂志,2002,22(5):282-284.
[9] 田蓉,匡安仁,秦卫仕,等.99Tc-MDP与免疫抑制疗法治疗Craves’眼病的对比研究.中华核医学杂志,2000,20(6):250-253.
[10] Hertz S,Roberts A,Salter WT.Radioactive iodine as an indicator in thyroid physiology.IV.The metabolism of iodine in Graves’ disease.J Clin Invest,1942,21(1):25-29.
[11] Wang RF,Tan J,Zhang GZ,et al.A comparative study of influential factors correlating with early and late hypothyroidism after 131I therapy for Graves’ disease.Chin Med J(Engl),2010,123(12):1528-1532.
[12] Baldys-Waligórska A,Stefańska A,Golkowski F,et al.Evaluation of radioiodine 131I treatment in Graves’ disease patients with mild orbitopathy.Przegl Lek,2009,66(4):166-169.
[13] Acharya SH,Avenell A,Philip S,et al.Radioiodine therapy(EAI) for Graves’s disease(GD) and the effect on ophthalmopathy:a systematic review.Clin Endocrinol(Oxf),2008,69(6):943-950.
[14] Bahn Chair RS,Burch HB,Cooper DS,et al.Hyperthyroidism and other causes of thyrotoxicosis:management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.Thyroid,2011,21(6):593-646.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[11]段炼,陆克义,陈霞,等.131I治疗Graves病对甲状腺相关眼病转归的相关因素分析[J].国际放射医学核医学杂志,2011,35(4):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
　DUAN Lian,LU Ke-yi,CHEN Xia,et al.Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
[12]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
　Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]

备注/Memo

备注/Memo:
收稿日期:2011-05-10。
通讯作者:谭建(Email:tanpost@163.com)
更新日期/Last Update: 1900-01-01